Tregalizumab

Drug Profile

Tregalizumab

Alternative Names: Biotherapeutic agent BT-061 - Biotest AG; BT-061

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Biotest
  • Developer Biotest AG
  • Class Antiasthmatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple sclerosis
  • Discontinued Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in Germany (Parenteral)
  • 30 Jun 2015 Discontinued - Phase-II for Plaque psoriasis in Czech Republic and Hungary (IV & SC)
  • 30 Jun 2015 Discontinued - Phase-II for Rheumatoid arthritis in USA, Bulgaria, Canada, Czech Republic, Estonia, Germany, Hungary, Italy, Latvia, Lithuania, Mexico, Poland, Russia, Serbia, Slovakia, Spain and Ukraine (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top